Imperial College London
Portrait Picture

DrSophieYacoub

Faculty of Medicine, Department of Infectious Disease

Honorary Clinical Research Fellow
 
 
 
//

Contact

 

s.yacoub

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Yacoub:2020:10.12688/wellcomeopenres.16053.1,
author = {Yacoub, S and Nguyen, NM and Chanh, HQ and Tam, DTH and Vuong, NL and Chau, NTX and Chau, NVV and Phong, NT and Trieu, HT and Luong, Thi Hue T and Cao, Thi T and Dinh, The T and Duyen, HTL and Van, NTT and Nguyen, Than Ha Q and Rivino, L and Gallagher, P and Jones, NK and Geskus, RB and Kestelyn, E},
doi = {10.12688/wellcomeopenres.16053.1},
journal = {Wellcome Open Research},
title = {Metformin as adjunctive therapy for dengue in overweight and obese patients: A protocol for an open-label clinical trial (MeDO)},
url = {http://dx.doi.org/10.12688/wellcomeopenres.16053.1},
volume = {5},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Dengue is a disease of major global importance. While most symptomatic infections are mild, a small proportion of patients progress to severe disease with risk of hypovolaemic shock, organ dysfunction and death. In the absence of effective antiviral or disease modifying drugs, clinical management is solely reliant on supportive measures. Obesity is a growing problem among young people in Vietnam and is increasingly recognised as an important risk factor for severe dengue, likely due to alterations in host immune and inflammatory pathways. Metformin, a widely used anti-hyperglycaemic agent with excellent safety profile, has demonstrated potential as a dengue therapeutic in vitro and in a retrospective observational study of adult dengue patients with type 2 diabetes. This study aims to assess the safety and tolerability of metformin treatment in overweight and obese dengue patients, and investigate its effects on several clinical, immunological and virological markers of disease severity. Methods: This open label trial of 120 obese/overweight dengue patients will be performed in two phases, with a metformin dose escalation if no safety concerns arise in phase one. The primary endpoint is identification of clinical and laboratory adverse events. Sixty overweight and obese dengue patients aged 10-30 years will be enrolled at the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam. Participants will complete a 5-day course of metformin therapy and be compared to a non-treated group of 60 age-matched overweight and obese dengue patients. Discussion: Previously observed antiviral and immunomodulatory effects of metformin make it a promising dengue therapeutic candidate in appropriately selected patients. This study will assess the safety and tolerability of adjunctive metformin in the management of overweight and obese young dengue patients, as well as its effects on markers of viral replication, endothelial dysfunction and host immune responses. Trial
AU  - Yacoub,S
AU  - Nguyen,NM
AU  - Chanh,HQ
AU  - Tam,DTH
AU  - Vuong,NL
AU  - Chau,NTX
AU  - Chau,NVV
AU  - Phong,NT
AU  - Trieu,HT
AU  - Luong,Thi Hue T
AU  - Cao,Thi T
AU  - Dinh,The T
AU  - Duyen,HTL
AU  - Van,NTT
AU  - Nguyen,Than Ha Q
AU  - Rivino,L
AU  - Gallagher,P
AU  - Jones,NK
AU  - Geskus,RB
AU  - Kestelyn,E
DO  - 10.12688/wellcomeopenres.16053.1
PY  - 2020///
TI  - Metformin as adjunctive therapy for dengue in overweight and obese patients: A protocol for an open-label clinical trial (MeDO)
T2  - Wellcome Open Research
UR  - http://dx.doi.org/10.12688/wellcomeopenres.16053.1
VL  - 5
ER  -
Download